DCTY Biotech EGFRvIII CAR Antibody Application, Apr 23
Summary
Beijing DCTY Biotech Co., Ltd. has filed Application US20260108607A1 with the USPTO covering an antibody targeting EGFRvIII and its use in chimeric antigen receptor (CAR) cell immunotherapy. The application, filed August 4, 2023 under Application No. 19100824, names Shuang Li, Zishan Zhou, Yujie Song, and Rong Zhang as inventors. The published application provides claims to the antibody or antigen-binding fragment thereof, a CAR incorporating the fragment, and therapeutic and detection uses. Biopharmaceutical companies developing CAR-T or targeted cancer immunotherapies targeting EGFRvIII should review this published application for potential freedom-to-operate considerations.
“Provided is an antibody targeting EGFRvIII or an antigen-binding fragment thereof.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
Beijing DCTY Biotech Co., Ltd. has published Application US20260108607A1 covering an antibody targeting EGFRvIII (or an antigen-binding fragment thereof), a CAR comprising that fragment, and methods of treating or detecting conditions using the foregoing. The application, with a filing date of August 4, 2023, names four inventors and includes CPC classifications spanning A61K (pharmaceutical compositions) and C07K (proteins/peptides), indicating therapeutic and immunological applications.\n\nBiopharmaceutical companies engaged in CAR-T development, targeted cancer immunotherapy, or EGFRvIII-directed oncology programs should monitor this published application for claims that may overlap with their own pipeline assets. While the application has not yet matured into an issued patent, it establishes a priority date that could affect later-filed applications in this technological space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTIBODY TARGETING EGFRVIII AND USE THEREOF IN CELL IMMUNOTHERAPY
Application US20260108607A1 Kind: A1 Apr 23, 2026
Assignee
BEIJING DCTY BIOTECH CO., LTD.
Inventors
Shuang LI, Zishan ZHOU, Yujie SONG, Rong ZHANG
Abstract
Provided is an antibody targeting EGFRvIII or an antigen-binding fragment thereof. Further provided are a CAR comprising the antigen-binding fragment targeting EGFRvIII, and treatment and detection use thereof.
CPC Classifications
A61K 40/4204 A61K 40/11 A61K 40/15 A61K 40/31 C07K 14/7051 C07K 16/2863 C07K 2317/24
Filing Date
2023-08-04
Application No.
19100824
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.